NLS Pharmaceutics AG (NLSP) Stock Analysis

What NLS Pharmaceutics AG does

NLS Pharmaceutics AG is a biopharmaceutical firm dedicated to researching and creating treatments for intricate and uncommon conditions affecting the central nervous system. Its primary focus includes advancing medications for narcolepsy, idiopathic hypersomnia, and various other unusual sleep conditions, alongside neurodevelopmental challenges like attention deficit hyperactivity disorder (ADHD). Key experimental compounds in its pipeline are Quilience, designed to address excessive daytime sleepiness and cataplexy, and Nolazol, which targets ADHD. Established in 2015, the company maintains its headquarters in Zurich, Switzerland.

Key metrics

ETFs linked to NLSP

Broad-market and Healthcare sector ETFs an investor holding NLS Pharmaceutics AG is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how NLSP fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for NLS Pharmaceutics AG?

NLS Pharmaceutics AG trades under the ticker NLSP on NASDAQ.

Which exchange is NLSP listed on?

NLSP is listed on NASDAQ.

What sector does NLS Pharmaceutics AG operate in?

NLS Pharmaceutics AG is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze NLSP in a portfolio?

PortView shows NLSP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.